Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 COVID-19 Vaccine Myth Busters January 28, 2021 Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... January 4, 2021 Load more HOT NEWS FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... CAR22 Shows Durable Efficacy After a Single Infusion in Patients with...
